{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:49:21Z","timestamp":1787827761811,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Italian Ministry of Health - Ricerca Corrente"},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"crossref","award":["Progetto Strategico AIFA - Interceptor"],"award-info":[{"award-number":["Progetto Strategico AIFA - Interceptor"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"crossref","award":["Progetto Strategico AIFA - Interceptor"],"award-info":[{"award-number":["Progetto Strategico AIFA - Interceptor"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"crossref","award":["Progetto Strategico AIFA - Interceptor"],"award-info":[{"award-number":["Progetto Strategico AIFA - Interceptor"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"crossref","award":["Progetto Strategico AIFA - Interceptor"],"award-info":[{"award-number":["Progetto Strategico AIFA - Interceptor"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"crossref","award":["Progetto Strategico AIFA - Interceptor"],"award-info":[{"award-number":["Progetto Strategico AIFA - Interceptor"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"crossref","award":["Progetto Strategico AIFA - Interceptor"],"award-info":[{"award-number":["Progetto Strategico AIFA - Interceptor"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"crossref","award":["Progetto Strategico AIFA - Interceptor"],"award-info":[{"award-number":["Progetto Strategico AIFA - Interceptor"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"crossref","award":["Progetto Strategico AIFA - Interceptor"],"award-info":[{"award-number":["Progetto Strategico AIFA - Interceptor"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"crossref","award":["Progetto Strategico AIFA - Interceptor"],"award-info":[{"award-number":["Progetto Strategico AIFA - Interceptor"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"crossref","award":["Progetto Strategico AIFA - Interceptor"],"award-info":[{"award-number":["Progetto Strategico AIFA - Interceptor"]}],"id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"DOI":"10.1186\/s12987-025-00620-5","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T11:49:25Z","timestamp":1737460165000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Exploring the ability of plasma pTau217, pTau181 and beta-amyloid in mirroring cerebrospinal fluid biomarker profile of Mild Cognitive Impairment by the fully automated Lumipulse\u00ae platform"],"prefix":"10.1186","volume":"22","author":[{"given":"Marcella","family":"Catania","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Battipaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Perego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Maderna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico Angelo","family":"Cazzaniga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo M.","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vanacore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Redolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Perani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Spadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cotelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Cappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naike","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Tiraboschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Tagliavini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Fede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"1","key":"620_CR1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","volume":"25","author":"CA Lane","year":"2018","unstructured":"Lane CA, Hardy J, Schott JM. Alzheimer\u2019s disease. Eur J Neurol. 2018;25(1):59\u201370.","journal-title":"Eur J Neurol"},{"issue":"7","key":"620_CR2","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40263-024-01097-w","volume":"38","author":"MH Rosenbloom","year":"2024","unstructured":"Rosenbloom MH, O\u2019Donohue T, Zhou-Clark D, Mala D, Frazier A, Tarrant M, et al. A Framework for the administration of anti-amyloid monoclonal antibody treatments in early-stage Alzheimer\u2019s Disease. CNS Drugs. 2024;38(7):493\u2013505.","journal-title":"CNS Drugs"},{"key":"620_CR3","doi-asserted-by":"publisher","first-page":"q1327","DOI":"10.1136\/bmj.q1327","volume":"385","author":"O Dyer","year":"2024","unstructured":"Dyer O, Donanemab. FDA experts recommend approval of Alzheimer\u2019s drug. BMJ. 2024;385:q1327.","journal-title":"BMJ"},{"key":"620_CR4","doi-asserted-by":"crossref","unstructured":"2023 Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2023;19(4):1598\u2009\u2013\u2009695.","DOI":"10.1002\/alz.13016"},{"key":"620_CR5","unstructured":"CR J. DA B, K B, MC C, B D, SB H, NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimer\u2019s Dement J Alzheimer\u2019s Assoc. 2018;14(4)."},{"issue":"5","key":"620_CR6","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.tips.2015.03.002","volume":"36","author":"K Blennow","year":"2015","unstructured":"Blennow K, Mattsson N, Sch\u00f6ll M, Hansson O, Zetterberg H. Amyloid biomarkers in Alzheimer\u2019s disease. Trends Pharmacol Sci. 2015;36(5):297\u2013309.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"620_CR7","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3233\/JAD-170128","volume":"61","author":"JD Doecke","year":"2018","unstructured":"Doecke JD, Rembach A, Villemagne VL, Varghese S, Rainey-Smith S, Sarros S, et al. Concordance between cerebrospinal fluid biomarkers with Alzheimer\u2019s Disease Pathology between three independent assay platforms. J Alzheimers Dis. 2018;61(1):169\u201383.","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"620_CR8","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1002\/alz.13413","volume":"19","author":"ZB Wang","year":"2023","unstructured":"Wang ZB, Tan L, Gao PY, Ma YH, Fu Y, Sun Y, et al. Associations of the A\/T\/N profiles in PET, CSF, and plasma biomarkers with Alzheimer\u2019s disease neuropathology at autopsy. Alzheimers Dement. 2023;19(10):4421\u201335.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"620_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3233\/JAD-150179","volume":"47","author":"M Catania","year":"2015","unstructured":"Catania M, Di Fede G, Tonoli E, Benussi L, Pasquali C, Giaccone G, et al. Mirror Image of the amyloid-beta species in cerebrospinal fluid and cerebral amyloid in Alzheimer\u2019s Disease. J Alzheimers Disease. 2015;47(4):877\u201381.","journal-title":"J Alzheimers Disease"},{"key":"620_CR10","doi-asserted-by":"publisher","first-page":"647783","DOI":"10.3389\/fnins.2021.647783","volume":"15","author":"G Bellomo","year":"2021","unstructured":"Bellomo G, Indaco A, Chiasserini D, Maderna E, Paolini Paoletti F, Gaetani L, et al. Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimer\u2019s Disease and Other Neurological disorders. Front Neurosci. 2021;15:647783.","journal-title":"Front Neurosci"},{"issue":"4","key":"620_CR11","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne VL, Dor\u00e9 V, Burnham SC, Masters CL, Rowe CC. Imaging tau and amyloid-\u03b2 proteinopathies in Alzheimer disease and other conditions. Nat Rev Neurol. 2018;14(4):225\u201336.","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"620_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3233\/JAD-150238","volume":"46","author":"TK Khan","year":"2015","unstructured":"Khan TK, Alkon DL. Alzheimer\u2019s Disease Cerebrospinal Fluid and Neuroimaging biomarkers: diagnostic accuracy and relationship to drug efficacy. J Alzheimers Dis. 2015;46(4):817\u201336.","journal-title":"J Alzheimers Dis"},{"key":"620_CR13","doi-asserted-by":"crossref","unstructured":"Mielke MM, Fowler NR. Alzheimer disease blood biomarkers: considerations for population-level use. Nat Rev Neurol. 2024;20(8):495\u2013504.","DOI":"10.1038\/s41582-024-00989-1"},{"key":"620_CR14","doi-asserted-by":"publisher","first-page":"119857","DOI":"10.1016\/j.cca.2024.119857","volume":"562","author":"K Rajendran","year":"2024","unstructured":"Rajendran K, Krishnan UM. Biomarkers in Alzheimer\u2019s disease. Clin Chim Acta. 2024;562:119857.","journal-title":"Clin Chim Acta"},{"key":"620_CR15","first-page":"e99010010","volume":"11","author":"Y Mu","year":"2024","unstructured":"Mu Y, Chang KX, Chen YF, Yan K, Wang CX, Hua Q. Diagnosis of Alzheimer\u2019s disease: towards accuracy and accessibility. J Biol Methods. 2024;11:e99010010.","journal-title":"J Biol Methods"},{"issue":"8","key":"620_CR16","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, et al. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13(8):841\u20139.","journal-title":"Alzheimers Dement"},{"issue":"17","key":"620_CR17","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93(17):e1647\u201359.","journal-title":"Neurology"},{"issue":"7691","key":"620_CR18","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554(7691):249\u201354.","journal-title":"Nature"},{"issue":"3","key":"620_CR19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med. 2020;26(3):379\u201386.","journal-title":"Nat Med"},{"issue":"5","key":"620_CR20","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333.","journal-title":"Lancet Neurol"},{"issue":"1","key":"620_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/ADR-230029","volume":"7","author":"MV Pais","year":"2023","unstructured":"Pais MV, Forlenza OV, Diniz BS. Plasma biomarkers of Alzheimer\u2019s disease: a review of available assays, recent developments, and implications for clinical practice. J Alzheimers Dis Rep. 2023;7(1):355\u201380.","journal-title":"J Alzheimers Dis Rep"},{"issue":"4","key":"620_CR22","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/alz.13687","volume":"20","author":"G Bellomo","year":"2024","unstructured":"Bellomo G, Bayoumy S, Megaro A, Toja A, Nardi G, Gaetani L, et al. Fully automated measurement of plasma A\u03b242\/40 and p-tau181: Analytical robustness and concordance with cerebrospinal fluid profile along the Alzheimer\u2019s disease continuum in two independent cohorts. Alzheimers Dement. 2024;20(4):2453\u201368.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"620_CR23","doi-asserted-by":"publisher","first-page":"e12545","DOI":"10.1002\/dad2.12545","volume":"16","author":"DJ Figdore","year":"2024","unstructured":"Figdore DJ, Wiste HJ, Bornhorst JA, Bateman RJ, Li Y, Graff-Radford J, et al. Performance of the Lumipulse plasma A\u03b242\/40 and pTau181 immunoassays in the detection of amyloid pathology. Alzheimers Dement (Amst). 2024;16(1):e12545.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"1","key":"620_CR24","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13195-023-01319-1","volume":"15","author":"F Mart\u00ednez-Dubarbie","year":"2023","unstructured":"Mart\u00ednez-Dubarbie F, Guerra-Ruiz A, L\u00f3pez-Garc\u00eda S, Lage C, Fern\u00e1ndez-Matarrubia M, Infante J, et al. Accuracy of plasma A\u03b240, A\u03b242, and p-tau181 to detect CSF Alzheimer\u2019s pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform. Alzheimers Res Ther. 2023;15(1):163.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"620_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13195-024-01397-9","volume":"16","author":"A Silva-Sp\u00ednola","year":"2024","unstructured":"Silva-Sp\u00ednola A, Leit\u00e3o MJ, Nadal A, Le Bastard N, Santana I, Baldeiras I. Exploring the potential of fully automated LUMIPULSE G plasma assays for detecting Alzheimer\u2019s disease pathology. Alzheimers Res Ther. 2024;16(1):51.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"620_CR26","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s13195-022-01116-2","volume":"14","author":"EN Wilson","year":"2022","unstructured":"Wilson EN, Young CB, Ramos Benitez J, Swarovski MS, Feinstein I, Vandijck M, et al. Performance of a fully-automated lumipulse plasma phospho-tau181 assay for Alzheimer\u2019s disease. Alzheimers Res Ther. 2022;14(1):172.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"620_CR27","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1007\/s00415-023-12148-5","volume":"271","author":"AJ Mendes","year":"2024","unstructured":"Mendes AJ, Ribaldi F, Lathuiliere A, Ashton NJ, Janelidze S, Zetterberg H, et al. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort. J Neurol. 2024;271(4):2053\u201366.","journal-title":"J Neurol"},{"issue":"3","key":"620_CR28","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"620_CR29","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3233\/JAD-190670","volume":"72","author":"PM Rossini","year":"2019","unstructured":"Rossini PM, Cappa SF, Lattanzio F, Perani D, Spadin P, Tagliavini F, et al. The Italian INTERCEPTOR Project: from the early identification of patients eligible for prescription of Antidementia Drugs to a Nationwide Organizational Model for Early Alzheimer\u2019s Disease diagnosis. J Alzheimers Dis. 2019;72(2):373\u201388.","journal-title":"J Alzheimers Dis"},{"key":"620_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/bs.pmbts.2019.07.006","volume":"168","author":"K Blennow","year":"2019","unstructured":"Blennow K, Zetterberg H. Fluid biomarker-based molecular phenotyping of Alzheimer\u2019s disease patients in research and clinical settings. Prog Mol Biol Transl Sci. 2019;168:3\u201323.","journal-title":"Prog Mol Biol Transl Sci"},{"issue":"Suppl 1","key":"620_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40120-017-0073-9","volume":"6","author":"K Blennow","year":"2017","unstructured":"Blennow K. A review of fluid biomarkers for Alzheimer\u2019s Disease: moving from CSF to blood. Neurol Ther. 2017;6(Suppl 1):15\u201324.","journal-title":"Neurol Ther"},{"issue":"9","key":"620_CR32","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/clinchem\/hvad103","volume":"69","author":"S Lehmann","year":"2023","unstructured":"Lehmann S, Schraen-Maschke S, Vidal JS, Delaby C, Blanc F, Paquet C, et al. Head-to-Head comparison of two plasma phospho-tau assays in Predicting Conversion of mild cognitive impairment to Dementia. Clin Chem. 2023;69(9):1072\u201383.","journal-title":"Clin Chem"},{"key":"620_CR33","doi-asserted-by":"crossref","unstructured":"Assfaw AD, Schindler SE, Morris JC. Advances in blood biomarkers for Alzheimer disease (AD): a review. Kaohsiung J Med Sci. 2024;40(8):692\u2013698.","DOI":"10.1002\/kjm2.12870"},{"issue":"1","key":"620_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13195-024-01521-9","volume":"16","author":"MD Howe","year":"2024","unstructured":"Howe MD, Britton KJ, Joyce HE, Menard W, Emrani S, Kunicki ZJ, et al. Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer\u2019s disease. Alzheimers Res Ther. 2024;16(1):154.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"620_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13195-024-01513-9","volume":"16","author":"J Arranz","year":"2024","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, Rodr\u00edguez-Baz \u00cd, Ferrer R, Carmona-Iragui M, et al. Diagnostic performance of plasma pTau. Alzheimers Res Ther. 2024;16(1):139.","journal-title":"Alzheimers Res Ther"},{"issue":"8","key":"620_CR36","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J, Chai X, Vemuri P, Lowe VJ, et al. Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 2018;14(8):989\u201397.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"620_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","volume":"144","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Rodriguez JL, Snellman A, et al. Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum. Brain. 2021;144(1):325\u201339.","journal-title":"Brain"},{"issue":"1","key":"620_CR38","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43587-020-00003-5","volume":"1","author":"NC Cullen","year":"2021","unstructured":"Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P, et al. Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nat Aging. 2021;1(1):114\u201323.","journal-title":"Nat Aging"},{"issue":"2","key":"620_CR39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/alz.12395","volume":"18","author":"S Janelidze","year":"2022","unstructured":"Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, et al. Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimers Dement. 2022;18(2):283\u201393.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"620_CR40","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1002\/alz.12751","volume":"19","author":"S Palmqvist","year":"2023","unstructured":"Palmqvist S, Stomrud E, Cullen N, Janelidze S, Manuilova E, Jethwa A, et al. An accurate fully automated panel of plasma biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 2023;19(4):1204\u201315.","journal-title":"Alzheimers Dement"},{"issue":"12","key":"620_CR41","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1038\/s41591-022-02074-w","volume":"28","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Janelidze S, Mattsson-Carlgren N, Binette AP, Strandberg O, Brum WS, et al. Differential roles of A\u03b242\/40, p-tau231 and p-tau217 for Alzheimer\u2019s trial selection and disease monitoring. Nat Med. 2022;28(12):2555\u201362.","journal-title":"Nat Med"},{"key":"620_CR42","doi-asserted-by":"crossref","unstructured":"Mart\u00ednez-Dubarbie F, Guerra-Ruiz A, L\u00f3pez-Garc\u00eda S, Irure-Ventura J, Lage C, Fern\u00e1ndez-Matarrubia M et al. Influence of physiological variables and comorbidities on plasma A\u03b240, A\u03b242, and p-tau181 levels in cognitively unimpaired individuals. Int J Mol Sci. 2024;25(3).","DOI":"10.3390\/ijms25031481"},{"issue":"9","key":"620_CR43","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1007\/s10072-023-06882-x","volume":"44","author":"F Verde","year":"2023","unstructured":"Verde F, Milone I, Dubini A, Colombrita C, Perego A, Solca F, et al. Influence of kidney function and CSF\/serum albumin ratio on plasma A\u03b242 and A\u03b240 levels measured on a fully automated platform in patients with Alzheimer\u2019s disease. Neurol Sci. 2023;44(9):3287\u201390.","journal-title":"Neurol Sci"},{"issue":"4","key":"620_CR44","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement. 2023;19(4):1403\u201314.","journal-title":"Alzheimers Dement"},{"issue":"9","key":"620_CR45","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jamaneurol.2023.2338","volume":"80","author":"P Erickson","year":"2023","unstructured":"Erickson P, Simr\u00e9n J, Brum WS, Ennis GE, Kollmorgen G, Suridjan I, et al. Prevalence and clinical implications of a \u03b2-Amyloid-Negative, tau-positive Cerebrospinal Fluid Biomarker Profile in Alzheimer Disease. JAMA Neurol. 2023;80(9):969\u201379.","journal-title":"JAMA Neurol"},{"issue":"9","key":"620_CR46","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","volume":"3","author":"WS Brum","year":"2023","unstructured":"Brum WS, Cullen NC, Janelidze S, Ashton NJ, Zimmer ER, Therriault J, et al. A two-step workflow based on plasma p-tau217 to screen for amyloid \u03b2 positivity with further confirmatory testing only in uncertain cases. Nat Aging. 2023;3(9):1079\u201390.","journal-title":"Nat Aging"},{"key":"620_CR47","doi-asserted-by":"crossref","unstructured":"Pradeepkiran JA, Baig J, Islam MA, Kshirsagar S, Reddy PH. Amyloid-beta and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer\u2019s Disease. Aging Dis. 2024. Epub ahead of print.","DOI":"10.14336\/AD.2024.0286"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-025-00620-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-025-00620-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-025-00620-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:44:36Z","timestamp":1737503076000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-025-00620-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1186\/s12987-025-00620-5","relation":{},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"14 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in compliance with the Declaration of Helsinki for the protection of human participants and was approved by the Ethics Committee of Fondazione Policlinico Universitario Agostino Gemelli (approval code 2251). Additionally, approval was obtained from all local ethics committees of the participating clinical centres. Written informed consent was obtained from participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"N\/A.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"A.P. is an employee of Fujirebio.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9"}}